Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Apnimed announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.

Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that Rob Rode has joined the company as Chief Commercial Officer. Mr. Rode has more than 27 years of experience leading global sales and marketing efforts in the biopharmaceutical field and will be responsible for developing and executing Apnimed’s commercial strategy.


By submitting this form, you are consenting to receive marketing emails from: Apnimed, 20 Holyoke Street, Cambridge, MA, 02138, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact